COVID-19 Leads To Less Industry Spend On Docs, But Not Necessarily Less Influence
Drug and medical device company payments to doctors and hospitals for non-research related activities dropped for the first time in 2020 since CMS’s Open Payments database began collecting the information.
You may also be interested in...
Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.
Companies should consider alternatives to in-person physician presentations given the risk of kickback violations, OIG says. Concerns addressed in Novartis corporate integrity agreement are broader than that case, Chief Counsel to the Inspector General Greg Demske explains in an interview.
Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.